Experimental antibody combo shows promise against tough cancers
Disease control
Completed
This study tested a new antibody called ICT01 combined with low-dose interleukin-2 (IL-2) in 56 people with advanced solid tumors like colorectal, ovarian, and pancreatic cancer. The goal was to see if the combo is safe and can shrink tumors. Early results suggest it may help con…
Phase: PHASE1, PHASE2 • Sponsor: ImCheck Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC